Yes, because it may impact potential partners getting involved in P2B combination therapy trial. ODD in EU gives 10 years market exclusivity amongst other advantages. It is definitely another de-risking event for ANP. There have also been hints by CEO around one big P2B concurrent trial in US and EU - with results being used to appease both FDA and EMA.
(20min delay)